Disparities in access to anti-HER2 therapies in neoadjuvant chemotherapy: A prognostic analysis based on real-world data comparing Brazil's public and private healthcare systems

Disparities in access to anti-HER2 therapies in neoadjuvant chemotherapy: A prognostic analysis based on real-world data comparing Brazil's public and private healthcare systems

Background: Trastuzumab has significantly improved the treatment of HER2-positive breast cancer, particularly in the neoadjuvant setting, where its combination with chemotherapy increases the pathologic complete response (pCR) rate. This retrospective cohort study assesses the implications of dispar...

Full description

Saved in:
Bibliographic Details
Main Authors: Marcelo Antonini, André Mattar, Denise Joffily Pereira da Costa Pinheiro, Isabela Bastos Maia, Marina Diógenes Teixeira, Andressa Gonçalves Amorim, Odair Ferraro, Larissa Chrispim de Oliveira, Marcellus do Nascimento Moreira Ramos, Francisco Pimentel Cavalcante, Felipe Zerwes, Marcelo Madeira, Romualdo Barroso-Sousa, Eduardo de Camargo Millen, Antonio Luiz Frasson, Fabricio Palermo Brenelli, Gil Facina, Rogério Fenile, Luiz Henrique Gebrim, Juliana Monte Real
Format: Article
Language:English
Published: Elsevier 2025-04-01
Series:Breast
Subjects:
Breast cancer
Neoadjuvant chemotherapy
Disparity
Equity
Trastuzumab
Overall survival
Online Access:http://www.sciencedirect.com/science/article/pii/S0960977625000360
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items